NCT03508869View on ClinicalTrials.gov

Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea

NATerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 27, 2016

Primary Completion Date

September 20, 2017

Study Completion Date

September 20, 2017

Conditions
Erythema and Flushing Associated With Rosacea
Interventions
DRUG

Mirvaso® (brimonidine) topical gel, 0.33%

Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.

DRUG

Dysport®

Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.

DRUG

Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%

Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%

Sponsors

Collaborators (1)

Galderma R&D
All Listed Sponsors
collaborator

Galderma R&D

INDUSTRY

lead

Skin Laser & Surgery Specialists

OTHER